The fallout for Venture Global Inc., in the wake of a troubled initial public offering, accelerated amid a market selloff ...

HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Even so the deal solidifies Venture Global’s place in the public markets with an impressive $50 billion market cap. And it ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Venture Global's IPO represents a test for investor appetite for fossil fuel projects in the Trump administration.

The stock market trading debut comes as incoming President Trump has said he plans to boost America’s energy production.

The Trump administration has made very clear they support growing LNG exports,” Venture CEO Mike Sable told CNBC in an ...

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

Learn about Karman Holdings' upcoming $100 million US IPO, their focus on missile and space systems, and the financial ...

Rexpro Enterprises IPO shows a grey market premium of ₹10, indicating a potential listing price of ₹155. The IPO was ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...